All data are based on the daily closing price as of October 28, 2026
s

Sysmex

6869.TSE
12.27 USD
-0.14
-1.13%

Overview

Last close
12.27 usd
Market cap
7.39B usd
52 week high
18.55 usd
52 week low
8.27 usd
Target price
13.56 usd

Valuation

P/E
30.7011
Forward P/E
27.933
Price/Sales
2.245
Price/Book Value
2.4338
Enterprise Value
7.55B usd
EV/Revenue
2.2689
EV/EBITDA
11.0578

Key financials

Revenue TTM
3.33B usd
Gross Profit TTM
1.70B usd
EBITDA TTM
731.47M usd
Earnings per Share
0.4 usd
Dividend
0.23 usd
Total assets
4.59B usd
Net debt
60.84M usd

About

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers hematology, a major test routinely included in blood tests; Flow Cytometry (FCM) analyzes cell properties by irradiating individual cells with a laser and measuring the intensity of light scattering and fluorescence; urinalysis test checks for the presence of glucose, proteins, and blood in urine; clinical chemistry; hemostasis; immunochemistry; cancer gene testing; and antimicrobial susceptibility testing. The company also provides Caresphere, an ICT solution, which integrates and analyzes real time various data managed through testing instruments and clinical testing information systems, and supports the efficient operation of clinical laboratories; and involved in the medical robotics business. It serves products and services to medical institutions, clinical laboratories, animal hospitals, and research institutes. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.
  • Symbol
    6869.TSE
  • Exchange
    TSE
  • Isin
    JP3351100007
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Medical Devices
  • CEO
    Mr. Hisashi Ietsugu
  • Headquarter
    Kobe
  • Web site
    https://www.sysmex.co.jp
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top